Table 1 Comparison with the guidelines of the drugs studied in the published articles and the ongoing RCTs for the three prevalent diseases
From: Globalization of pediatric research: pharmacological RCTs in Latin America
Condition Investigated | Published (2000–2015) | Guidelines | Treatment | Ongoing (2015) |
|---|---|---|---|---|
Asthma | Salbutamol (SABA) | GINA (The Global Initiative for Asthma) 2015 | Step 1: SABA | Fluticasone/Salmeterol (ICS + LABA) |
Formoterol (LABA) | Step 2: low dose ICS + SABA | Beclometasone dipropionate (ICS) | ||
Salmeterol (LABA) | Step 3: low dose ICS/LABA + SABA | Budesonide/Formoterol (ICS + LABA) | ||
Montelukast (LTRA) | Step 4: medium dose ICS/LABA + SABA | Dexamethasone/Epinephrine (ICS) | ||
Fluticasone (ICS) | Step 5: add-on treatment (omalizumab or tiotropium) | Salbutamol (SABA) | ||
Budesonide (ICS) | Magnesium Sulphate | |||
Aminophylline | Lebrikizumab | |||
Triamcinolone | ||||
CAP | Amoxicillin | IDSA (The Infectious Diseases Society of America) 2013 | Outpatients | |
Azithromycin | Amoxicillin | |||
Chloramphenicol | Macrolide antibiotic | |||
Inpatients | ||||
First line: Ampicillin or Penicillin G | ||||
Second line: Ceftriaxone or Cefotaxime | ||||
Macrolide + β-lactam antibiotic | ||||
Vancomycin or Clindamycin + β-lactam antibiotic | ||||
Viral Pneumonia | Palivizumab | Influenza | Oseltamivir | |
Motavizumab | Amantadine or Rimantadine | MEDI8897 | ||
Oseltamivir or Zanamivir | ALS-008176 | |||
RSV | REGN2222 | |||
Palivizumab | JNJ-53718678 | |||
Ribavirin | ||||
Giardiasis | Mebendazole | WGO (The World Gastroenterology Organization) 2012 | First line: Metronidazole | |
Albendazole | Second line: Tinidazole or Ornidazole | |||
Nitazoxanide | ||||
Chloroquine | ||||
Tinidazole |